NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,991,826 | -4.6% | 253,413 | +21.2% | 0.00% | – |
| Q2 2023 | $2,088,880 | -7.0% | 209,097 | -17.3% | 0.00% | – |
| Q1 2023 | $2,245,860 | -48.9% | 252,912 | -36.8% | 0.00% | – |
| Q4 2022 | $4,396,634 | -29.8% | 400,422 | -16.7% | 0.00% | -100.0% |
| Q3 2022 | $6,262,000 | -15.1% | 480,542 | -17.4% | 0.00% | 0.0% |
| Q2 2022 | $7,376,000 | -22.7% | 582,105 | -14.5% | 0.00% | 0.0% |
| Q1 2022 | $9,538,000 | +281.5% | 680,859 | +688.8% | 0.00% | – |
| Q4 2021 | $2,500,000 | -40.2% | 86,321 | -38.2% | 0.00% | -100.0% |
| Q3 2021 | $4,181,000 | -64.4% | 139,573 | -68.5% | 0.00% | -50.0% |
| Q2 2021 | $11,753,000 | +301.9% | 443,038 | +371.1% | 0.00% | – |
| Q1 2021 | $2,924,000 | +911.8% | 94,043 | +969.0% | 0.00% | – |
| Q4 2020 | $289,000 | +381.7% | 8,797 | +409.1% | 0.00% | – |
| Q3 2020 | $60,000 | – | 1,728 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |